Another Trip for the ‘Shroom’ Stocks

As a clinical psychologist at Harvard University, Leary worked on the Harvard Psilocybin Project from 1960 to 1962 (LSD and psilocybin were still legal in the United States at the time), resulting in the Concord Prison Experiment and the Marsh Chapel Experiment. The scientific legitimacy and ethics of his research were questioned by other Harvard faculty because he took psychedelics along with research subjects and pressured students to join in.[6][7][8] Leary and his colleague, Richard Alpert (who later became known as Ram Dass), were fired from Harvard University in May 1963.[9] Most people first heard of psychedelics after the Harvard scandal.[10]

Leary believed that LSD showed potential for therapeutic use in psychiatry.” –Wikipedia

A man ahead of his time? I believe the therapy has merit.


Back in the casino, the rolling speculations we call financial markets have rotated back into the shrooms. After a ridiculous 220% trade in MMEDF that was a neck snapping 2 weeks in duration I took a short-term trade in it and only made a normal profit (10%? 20%? I can’t remember).

Then I bought back MMEDF and added CMPS for good measure to hold as part of a pretty diverse portfolio. Then, this… it’s a good start.

cmps & mmedf

For “best of breed” top down analysis of all major markets, subscribe to NFTRH Premium, which includes an in-depth weekly market report, detailed interim market updates and NFTRH+ dynamic updates and chart/trade setup ideas. You can also keep up to date with actionable public content at by using the email form on the right sidebar. Follow via Twitter @NFTRHgt.